Lightnews — Scholar-powered news

Jen L, PhD

@drjkyl.bsky.social

2.3K followers 13K following 240 posts

Executive Editor/Team Leader Open Access Science Journals Sage Publishing Opinions = mine http://linkedin.com/in/jlovick-editor #oncology #cancerresearch #medicine #biology #cardiology #neurology #microbiology #publichealth #healthcare #technology

linkedin.com

Posts Media Videos Starter Packs

Pinned

Jen L, PhD @drjkyl.bsky.social · Feb 21

Introduction - PhD working in academic publishing, lead a team of amazing Managing Editors that support @sagepub.com @journals.sagepub.com 's Open Access Biomedical Journals. I'll be sharing recent articles from our journals that I find interesting. Happy to connect with researchers! 📖🔬🧪💊⚕️

1 14

Reposted by Jen L, PhD

Lingling Tian @linglingtian.bsky.social · 23h

🚨 Call for Papers – Special Collection! @tamedoncol.bsky.social seeks submissions on: De-escalation of Treatment in Gynecologic Cancers. 🗓️ Submit by March 18, 2026 📥 Submit:

buff.ly

2 2

Reposted by Jen L, PhD

Therapeutic Advances in Infectious Disease @tainfdis.bsky.social · 17h

Systematic review/meta-analysis (2013–2024, n=23,319): In febrile neutropenia after chemotherapy, bloodstream infections were 59% Gram-negative, 39.7% Gram-positive, and 2.5% fungal.
journals.sagepub.com/doi/full/10....

Sage Journals: Discover world-class research

Subscription and open access journals from Sage, the world's leading independent academic publisher.

journals.sagepub.com

2 2

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 14h

In patients with metastatic #gastriccancer, earlier nivolumab monotherapy infusions (before 14:00) were associated with significantly longer PFS and OS (7.6 vs 3.9 mo). Authors suggest infusion timing may influence outcomes in #Immunotherapy practice.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 14h

In HER2-mutated non-small-cell lung cancer, combination regimens achieved markedly better outcomes than single-agent approaches.
Median PFS: 7.8 vs 5.3 mo; best results seen with chemo + immunotherapy + anti-angiogenic therapy.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 14h

In HER2+ salivary duct carcinoma, trastuzumab-deruxtecan (T-Dxd) achieved 13 months of disease control in a multitreated 44-year-old patient, supporting further study of anti-HER2 therapy in rare salivary tumors.

🔗 journals.sagepub.com/doi/epdf/10....

#HER2 #SalivaryCancer #Oncology

1 1

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 14h

In HR+ advanced #BreastCancer progressing after CDK4/6 inhibitors, network meta-analysis (19 RCTs; n=6621) found CDK4/6i + fulvestrant most effective for PFS, especially in visceral metastases or ESR1 mutations; Bcl-2i + Ful and SERDs also showed benefit

journals.sagepub.com/doi/epdf/10....

1 1

Reposted by Jen L, PhD

Therapeutic Advances in Medical Oncology @tamedoncol.bsky.social · 14h

In non-metastatic HER2− #BreastCancer, NCDB data (2018) showed higher pCR rates with neoadjuvant chemo in HR-Low vs HR-High groups. HR-Low tumors had higher grade/stage and lower endocrine therapy use, underscoring need for clearer treatment guidance.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 14h

In #ParkinsonsDisease, orthostatic hypotension (OH) is a disabling feature linked to poor quality of life and fall risk. This review summarizes pharmacologic and nonpharmacologic strategies for managing OH in PD.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 14h

In rescue stenting after failed thrombectomy, dual antiplatelet therapy post-procedure improved outcomes and reduced mortality and stent occlusion vs single therapy. Most occlusions occurred within 24 h, underscoring early management importance.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Reposted by Jen L, PhD

Therapeutic Advances in Neurological Disorders @taneuroldisord.bsky.social · 14h

In #ALS, analysis of 636 patients (2013–2023) found racial and ethnic disparities in care: Non-Hispanic Black patients had higher tracheostomy rates, and Hispanic patients were less likely to receive riluzole. Survival was similar across groups.

🔗 journals.sagepub.com/doi/epdf/10....

1 1

Reposted by Jen L, PhD

Lingling Tian @linglingtian.bsky.social · 3d

🧬 Article collection on @tamedoncol.bsky.social: PARPi in Gynecologic Cancers. This collection highlights research on HRR genetic landscape, PARPi outcomes, oxaliplatin sequencing in BRCA-mutated ovarian cancer, and PARPi resistance with combination strategies. 📚 Explore more

buff.ly

1 1

Reposted by Jen L, PhD

Lingling Tian @linglingtian.bsky.social · 2d

Zolbetuximab is gaining attention as a targeted therapy for CLDN18.2-positive gastric and GEJ cancers.
This review dives into the science behind Claudin18.2 and the clinical promise of zolbetuximab, backed by SPOTLIGHT and GLOW trial data.
buff.ly/ok6eO7y
#Oncology #GastricCancer #Zolbetuximab

1 1

Reposted by Jen L, PhD

Cancer Control @cancer-control.bsky.social · 4d

BRCA1/2-mutant early #BreastCancer: review urges region-tailored testing in Latin America, MRI-first screening, and shared surgical decision making. Neo-adjuvant platinum can raise pCR, while adjuvant olaparib improves OS. #BRCA #TNBC #PARPi #Latam

1 2

Reposted by Jen L, PhD

Lingling Tian @linglingtian.bsky.social · 5d

Lung cancer is varying by region in risks and traits. A new article examines carcinogens, genetic predisposition, and molecular epidemiology. We seek submissions on geographic differences in lung cancer. Deadline: Dec 31, 2025 🔗 buff.ly/JCo9lJP #CancerResearch #LungCancer #GlobalHealth